Comparative Pharmacology
Head-to-head clinical analysis: FOSAPREPITANT DIMEGLUMINE versus PROCHLORPERAZINE EDISYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAPREPITANT DIMEGLUMINE versus PROCHLORPERAZINE EDISYLATE.
FOSAPREPITANT DIMEGLUMINE vs PROCHLORPERAZINE EDISYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosaprepitant dimeglumine is a prodrug of aprepitant, a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. It inhibits emesis by blocking NK1 receptors in the central nervous system, particularly in the area postrema and the nucleus tractus solitarius.
Prochlorperazine is a phenothiazine antipsychotic that antagonizes dopamine D2 receptors in the brain, particularly in the chemoreceptor trigger zone, exerting antiemetic effects. It also blocks alpha-adrenergic and muscarinic receptors.
150 mg intravenous over 30 minutes on day 1, combined with dexamethasone and a 5-HT3 antagonist; alternatively, 115 mg IV on day 1 followed by 80 mg IV on day 2 and 80 mg IV on day 3, or 150 mg oral (as fosaprepitant dimeglumine or aprepitant) on day 1 and 80 mg oral on days 2 and 3.
Antiemetic: 5-10 mg IM/IV every 3-4 hours as needed, maximum 40 mg/day; or 25 mg PR twice daily. Antipsychotic: 10-20 mg IM/IV every 1-4 hours, maximum 40 mg/day; oral: 5-10 mg 3-4 times daily, maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life of aprepitant is approximately 9 to 13 hours; clinical significance includes once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Terminal elimination half-life is approximately 6-8 hours, but may be prolonged to 10-12 hours in elderly patients or those with hepatic impairment. In overdoses, half-life can extend beyond 24 hours.
Fosaprepitant is rapidly converted to aprepitant. Aprepitant is eliminated primarily by metabolism; <5% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 58% of the dose, and urinary excretion accounts for 43% (mostly as metabolites).
Primarily renal excretion of metabolites (approximately 70-80% as conjugated metabolites), with less than 1% excreted unchanged. Fecal excretion accounts for about 20-30% via biliary elimination.
Category C
Category A/B
Antiemetic
Typical Antipsychotic / Antiemetic